Form 8-K - Current report:
SEC Accession No. 0001731122-25-001033
Filing Date
2025-07-28
Accepted
2025-07-25 19:26:16
Documents
15
Period of Report
2025-07-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e6735_8k.htm   iXBRL 8-K 28595
2 EXHIBIT 1.1 e6735_ex1-1.htm EX-1.1 211546
3 EXHIBIT 5.1 e6735_ex5-1.htm EX-5.1 7435
4 GRAPHIC image_001.jpg GRAPHIC 3741
  Complete submission text file 0001731122-25-001033.txt   476863

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE avxl-20250725.xsd EX-101.SCH 3008
6 XBRL LABEL FILE avxl-20250725_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE avxl-20250725_pre.xml EX-101.PRE 22354
17 EXTRACTED XBRL INSTANCE DOCUMENT e6735_8k_htm.xml XML 3673
Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37606 | Film No.: 251152751
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)